Skip to content

Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus

Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00237640
Enrollment
85
Registered
2005-10-12
Start date
2005-03-31
Completion date
2007-07-31
Last updated
2008-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Adult Onset

Keywords

Cinnamon, Diabetes mellitus, Hyperlipidemia, Insulin Resistance

Brief summary

The purpose of this study is to determine the effects of cinnamon on serum glucose and lipid levels in people with non-insulin dependent type 2 diabetes mellitus.

Detailed description

Forty people with non-insulin dependent type 2 diabetes mellitus will be randomized to receive either cinnamon or placebo for three months. The dose of cinnamon will be one gram daily. Fasting serum glucose, triglyceride, total cholesterol, LDL, HDL, and insulin levels will be measured at baseline and at 1, 2, and 3 months. HbA1c levels will be measured at baseline and at 3 months. Patients will be monitored for compliance, adverse effects, and dietary changes.

Interventions

DRUGCinnamon or placebo 500 mg capsule twice daily

Cinnamon 500 mg capsule twice daily or placebo capsule twice daily

Sponsors

National Center for Research Resources (NCRR)
CollaboratorNIH
University of Oklahoma
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Type 2 diabetes mellitus * HbA1C \> 6.0% * Age 18 and above * Able to obtain consent

Exclusion criteria

* Currently taking insulin * Pregnancy * End-stage renal disease * Hemolytic anemia * Cinnamon intolerance * Inability or unwillingness to adhere to study protocol

Design outcomes

Primary

MeasureTime frame
- Primary outcomes include HbA1c, glucose, total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides levels.3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026